Watching GALECTIN THERAPEUTICS INC? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsMaterial AgreementItem 1.01 · 8-KMEDIUM RiskMixed
GALECTIN THERAPEUTICS INC
galectintherapeutics.comFiled: Jul 31, 2026Norcross, GeorgiaCIK: 0001359054Healthcare
AI Executive Summary
AI-powered analysis of 8-K filing content
Galectin Therapeutics converted $81 million in outstanding convertible promissory notes into 34.4 million shares of common stock issued to Chairman Richard E. Uihlein on July 31, 2026, converting debt into equity and strengthening the company's capital structure.
Key Takeaways
Conversion of $81 million in debt obligations into equity eliminates significant debt burden and improves balance sheet leverage ratios
Issuance of 34.4 million shares to the Chairman represents substantial dilution to existing shareholders but consolidates credit facilities
2 more takeaways
Filing Overview
Form Type8-K
Filing DateJul 31, 2026
Item1.01
CategoryMaterial Agreement
CIK0001359054
Accession #0001359054-26-000030
Risk LevelMEDIUM
SentimentMixed
Signalopportunity
Topics
debt financingstock offering
What This Means
The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.